Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
International Journal of Paleopathology
|
May 21, 2018
A case of benign osteogenic tumour in Homo naledi: Evidence for peripheral osteoma in the U.W. 101-1142 mandible
Edward J Odes, Lucas K Delezene, Patrick S Randolph-Quinney, et al.
Facial Plastic Surgery Clinics of North America
|
March 22, 2008
Roundtable: discussion of "the difficult patient"
Bruce F Connell, Jack Gunter, Toby Mayer, et al.
British Journal of Cancer
|
May 26, 2011
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
G K Schwartz, P M LoRusso, M A Dickson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2008
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
M Crump, B Coiffier, E D Jacobsen, et al.
Current Medical Research and Opinion
|
February 20, 2016
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment
T Bell, J P Crown, I Lang, et al.
Journal of Molecular Biology
|
May 30, 2020
Out-of-Register Parallel β-Sheets and Antiparallel β-Sheets Coexist in 150-kDa Oligomers Formed by Amyloid-β(1-42)
Yuan Gao, Cong Guo, Jens O Watzlawik, et al.
Scientific Reports
|
October 14, 2015
Evidence of fatal skeletal injuries on Malapa Hominins 1 and 2
Ericka N L'Abbé, Steven A Symes, James T Pokines, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2011
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer
Keith T Flaherty, Patricia M Lorusso, Angela Demichele, et al.
Facial Plastic Surgery Clinics of North America
|
October 27, 2010
Office managers' forum
Samuel M Lam, Launa Hankins, Andrea Dieter, et al.
Haematologica
|
April 10, 2025
Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study
Tae Min Kim, Nehal J Lakhani, Jacob Soumerai, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
International Journal of Paleopathology
|
May 21, 2018
A case of benign osteogenic tumour in Homo naledi: Evidence for peripheral osteoma in the U.W. 101-1142 mandible
Edward J Odes, Lucas K Delezene, Patrick S Randolph-Quinney, et al.
Facial Plastic Surgery Clinics of North America
|
March 22, 2008
Roundtable: discussion of "the difficult patient"
Bruce F Connell, Jack Gunter, Toby Mayer, et al.
British Journal of Cancer
|
May 26, 2011
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
G K Schwartz, P M LoRusso, M A Dickson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2008
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
M Crump, B Coiffier, E D Jacobsen, et al.
Current Medical Research and Opinion
|
February 20, 2016
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment
T Bell, J P Crown, I Lang, et al.
Journal of Molecular Biology
|
May 30, 2020
Out-of-Register Parallel β-Sheets and Antiparallel β-Sheets Coexist in 150-kDa Oligomers Formed by Amyloid-β(1-42)
Yuan Gao, Cong Guo, Jens O Watzlawik, et al.
Scientific Reports
|
October 14, 2015
Evidence of fatal skeletal injuries on Malapa Hominins 1 and 2
Ericka N L'Abbé, Steven A Symes, James T Pokines, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2011
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer
Keith T Flaherty, Patricia M Lorusso, Angela Demichele, et al.
Facial Plastic Surgery Clinics of North America
|
October 27, 2010
Office managers' forum
Samuel M Lam, Launa Hankins, Andrea Dieter, et al.
Haematologica
|
April 10, 2025
Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study
Tae Min Kim, Nehal J Lakhani, Jacob Soumerai, et al.
Page
of 5